Cencora reports Q2 adjusted EPS $4.00, consensus $3.84

Reports Q2 revenue $80.7B, consensus $80.12B. “Cencora (COR) delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “Our teams are fueling our growth as they identify opportunities and customer-centric solutions that strengthen our value proposition as the partner of choice,” Mauch continued. “We are guided by our purpose and focused on our strategic drivers of digital transformation, investing in our talent and culture, prioritizing growth-oriented investments and increasing productivity.”